These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 3902200

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
    J Clin Oncol; 1986 Feb; 4(2):186-93. PubMed ID: 2868074
    [Abstract] [Full Text] [Related]

  • 6. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen.
    Mouridsen HT, Rose C, Engelsman E, Sylvester R, Rotmensz N.
    Eur J Cancer Clin Oncol; 1985 Mar; 21(3):291-9. PubMed ID: 3891357
    [Abstract] [Full Text] [Related]

  • 7. How to improve adjuvant treatment results in postmenopausal patients.
    Mouridsen HT.
    Recent Results Cancer Res; 1989 Mar; 115():144-52. PubMed ID: 2533698
    [No Abstract] [Full Text] [Related]

  • 8. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PL, Bramwell VH, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA.
    J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
    [Abstract] [Full Text] [Related]

  • 9. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
    Mathé G, Misset JL, Plagne R, Reizenstein P, Belpomme D, Le Mevel B, Guerrin J, Fumoleau P, Metz R, Delgado M.
    Drugs Exp Clin Res; 1986 Jun; 12(1-3):143-5. PubMed ID: 3525068
    [Abstract] [Full Text] [Related]

  • 10. Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.
    Glick JH, Creech RH, Torri S, Holroyde C, Brodovsky H, Catalano RB, Varano M.
    Breast Cancer Res Treat; 1981 Jun; 1(1):59-68. PubMed ID: 6756508
    [Abstract] [Full Text] [Related]

  • 11. A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer. A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
    Cocconi G, Bisagni G, Bacchi M, Buzzi F, Canaletti R, Carpi A, Ceci G, Colozza A, De Lisi V, Lottici R.
    Ann Oncol; 1990 Jun; 1(1):36-44. PubMed ID: 2078484
    [Abstract] [Full Text] [Related]

  • 12. Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients.
    Pannuti F, Martoni A, Cilenti G, Camaggi CM, Fruet F.
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):423-9. PubMed ID: 2968262
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG, Kalish LA, Olson JE, Cummings F, Bennett JM, Falkson G, Tormey DC, Carbone PP.
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [Abstract] [Full Text] [Related]

  • 14. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR, De Placido S, Gallo C, Pagliarulo C, Marinelli A, Petrella G, D'Istria M, Delrio G.
    Lancet; 1988 Nov 12; 2(8620):1095-9. PubMed ID: 2903322
    [Abstract] [Full Text] [Related]

  • 15. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
    Pinnamaneni K, Yap HY, Buzdar AU, Distefano A, Blumenschein GR.
    Cancer; 1984 May 01; 53(9):1841-4. PubMed ID: 6546706
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
    Kaufmann M, Jonat W, Abel U, Hilfrich J, Caffier H, Kreienberg R, Trams G, Brunnert K, Schermann J, Kleine W.
    J Clin Oncol; 1993 Mar 01; 11(3):454-60. PubMed ID: 8445420
    [Abstract] [Full Text] [Related]

  • 17. A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization.
    Lippman ME, Cassidy J, Wesley M, Young RC.
    J Clin Oncol; 1984 Jan 01; 2(1):28-36. PubMed ID: 6321686
    [Abstract] [Full Text] [Related]

  • 18. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    Ejlertsen B, Jensen MB, Elversang J, Rasmussen BB, Andersson M, Andersen J, Nielsen DL, Cold S, Mouridsen HT.
    Eur J Cancer; 2013 Sep 01; 49(14):2986-94. PubMed ID: 23756360
    [Abstract] [Full Text] [Related]

  • 19. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women.
    Taylor SG, Gelman RS, Falkson G, Cummings FJ.
    Ann Intern Med; 1986 Apr 01; 104(4):455-61. PubMed ID: 3513684
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
    Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, Korzun A, Ginsberg S, Holland JF.
    J Clin Oncol; 1987 Oct 01; 5(10):1523-33. PubMed ID: 3655855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.